New publications

Interpharm is pleased to announce publication of a new report by FirstWord Biobetters: Major Players and Market Prospects that looks at the way that Biobetters are attracting growing interest at the same time as the Biosimilars market seems to be stalling.

The market for biological medicines is over $100bn, highly profitable and growing fast. This is a great temptation for makers of biosimilar products who want to capture a share of the market by introducing a cheaper copy. Biosimilars, though, have not proved as lucrative as the pioneers had hoped, and so many companies are now shifting their sights to biobetters.

For some, biobetters—drugs similar but superior to the branded reference product—are little more than the natural outcome of a drug’s life-cycle management strategy.

Even so, interest in biobetters is increasing, since they can and will command higher prices while providing a significant improvement to the reference drug. At the forefront of those turning to biobetters are branded pharma, biotech and large generic companies who have already established themselves in the biosimilars industry. But will the emerging biobetter industry prove to be more lucrative than has been the case for biosimilars?

• Publication date: September 2011
• Product code: 400200055
• Format: PDF
• Pages: 48

Interpharm has also continued to work with Decision Resources during 2010 and 2011 to prepare a series of reports on a variety of topics including:

• U.S. Healthcare Reform: Impact on the Pharmaceutical Industry
• Licensing Opportunities: Neurology
• Licensing Opportunities: Rheumatology
• Drug Price/Cost Debate: Coping with Escalating Pricing Pressures

For more details please see the Decision Resources website

Previous publications

In association with Decision Resources International, Interpharm also helped with the publication of a report in May 2008 - Asia: Threat or Opportunity?

Asian economic might is growing, and the Asian pharmaceutical markets and industry are growing along with it. Western pharmaceutical companies have become very interested in entering Asian markets and taking advantage of the opportunities they offer. Cost cutting alone, however, should not be the sole reason for multinational companies (MNCs) to outsource activities to Southeast Asia. Companies must make the effort to understand the local culture and business environment in each country they want to enter if they are to avoid unrealistic expectations and disappointments. The negative long-term effects could overshadow the benefits of short-term gains. Although Asian markets may prove challenging, they also offer significant opportunities for companies that focus their needs and then execute well-conceived strategies in specific countries.

Detailed information about the paper is available on the DRI site

January 2008 saw the publication of Indian Generics, 2008-2012: The Growing Threat to Westernised Markets by Interpharm, in association with Spectra Intelligence. More information can be found on the Spectra web site.

The report looks at issues such as why India has become such a pharmaceutical force and examines the commercial, strategic and regulatory background to their success.

Indian pharmaceutical companies are grabbing headlines on an almost daily basis and are increasingly carving out market shares for themselves in the US and many other markets around the world. Several leading Indian pharmaceutical companies have applied themselves to the challenge of entering Western markets with great success.

These companies now present a very serious threat to the existing Western generic companies in their domestic markets as they take ever-larger market shares and increase the levels of competition.

Why has this challenge arisen - what advantages do Indian companies enjoy that enable them to compete so successfully with Western generic companies? It is the purpose of this report to answer that question and to provide Western pharmaceutical companies and others that are interested by this phenomenon with some explanation of the background.

To read my most recent article for the GenericsWeb newsletter please use the link on the menu at the left or else click here to reach the page with the article

For information about my other published reports, please see the Publications section of About Interpharm.